Payment overview · 2025
General Payments
$36,447.49
146 reported records · 11 companies
Healthcare provider profile · identity verified
Daniel Sean Stewart, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · LOUISVILLE, KY · NPI 1770701237
Verified facts
What the public records show
CMS Open Payments records show Daniel Sean Stewart, M.D. received $36,447.49 in general payments during 2025 across 146 reported records.
Amgen Inc. accounted for 44.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $16,335.92 | 44.8% | 16 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $9,767.56 | 26.8% | 51 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$7,027.06 | 19.3% | 23 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $2,306.65 | 6.3% | 17 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $369.52 | 1.0% | 12 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $275.41 | 0.8% | 7 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $144.09 | 0.4% | 15 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $123.85 | 0.3% | 1 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $51.45 | 0.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $26.67 | 0.1% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $19.31 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $15,634.50 | 8 |
| Consulting Fee | $12,675.00 | 4 |
| Food and Beverage | $4,928.72 | 119 |
| Travel and Lodging | $3,209.27 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16,321.66 | 15 | 2025 |
Source payment records
|
|||||
| General - Balloons Normalized: general balloons |
Device | Boston Scientific Corporation | $7,573.61 | 5 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $5,457.21 | 8 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $1,074.58 | 11 | 2025 |
Source payment records
|
|||||
| General - Balloon Catheters Normalized: general balloon catheters |
Device | Boston Scientific Corporation | $342.53 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $337.70 | 11 | 2025 |
Source payment records
|
|||||
| EVOQUE Normalized: evoque |
Device | Edwards Lifesciences Corporation | $290.02 | 3 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $245.28 | 2 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $205.95 | 3 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $183.54 | 4 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $158.94 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $127.44 | 1 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $123.85 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $118.77 | 10 | 2025 |
Source payment records
|
|||||
| FFRANGIO Normalized: ffrangio |
Device | Medtronic, Inc. | $93.12 | 6 | 2025 |
Source payment records
|
|||||
| General - CT_IC Normalized: general ct ic |
Device | Boston Scientific Corporation | $80.15 | 1 | 2025 |
Source payment records
|
|||||
| General - Atherectomy Normalized: general atherectomy |
Device | Boston Scientific Corporation | $74.79 | 3 | 2025 |
Source payment records
|
|||||
| Clinical Trial Product Normalized: clinical trial product |
Device | Boston Scientific Corporation | $57.55 | 3 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $54.88 | 2 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $54.88 | 2 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $31.82 | 1 | 2025 |
Source payment records
|
|||||
| CDS - MCT/CEM Monitoring Normalized: cds mct cem monitoring |
Device | Boston Scientific Corporation | $30.03 | 1 | 2025 |
Source payment records
|
|||||
| Flextome Cutting Balloon Normalized: flextome cutting balloon |
Device | Boston Scientific Corporation | $27.29 | 1 | 2025 |
Source payment records
|
|||||
| MITRACLIP Normalized: mitraclip |
Device | Abbott Laboratories | $26.67 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Normalized: watchman |
Device | Boston Scientific Corporation | $25.89 | 2 | 2025 |
Source payment records
|
|||||
| General - Ultrasound Normalized: general ultrasound |
Device | Boston Scientific Corporation | $25.70 | 1 | 2025 |
Source payment records
|
|||||
| MANTA Normalized: manta |
Device | Teleflex LLC | $23.63 | 1 | 2025 |
Source payment records
|
|||||
| ACURATEPrimeAortic Valve XL Normalized: acurateprimeaortic valve xl |
Device | Boston Scientific Corporation | $21.49 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $19.31 | 1 | 2025 |
Source payment records
|
|||||
| FilterWire EZ Normalized: filterwire ez |
Device | Boston Scientific Corporation | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $14.58 | 2 | 2025 |
Source payment records
|
|||||
| Sentinel Normalized: sentinel |
Device | Boston Scientific Corporation | $13.61 | 1 | 2025 |
Source payment records
|
|||||
| ONYX FRONTIER Normalized: onyx frontier |
Device | Medtronic, Inc. | $5.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
112 | 38 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 295 | 94 |
| Carvedilol | Carvedilol | 137 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 133 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 122 | 44 |
| Brilinta | Ticagrelor | 112 | 38 |
| Eliquis | Apixaban | 100 | 29 |
| Atorvastatin Calcium | Atorvastatin Calcium | 96 | 33 |
| Warfarin Sodium | Warfarin Sodium | 90 | 15 |
| Metoprolol Succinate | Metoprolol Succinate | 83 | 30 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 65 | 23 |
| Furosemide | Furosemide | 60 | 20 |
| Losartan Potassium | Losartan Potassium | 60 | 23 |
| Irbesartan | Irbesartan | 57 | 18 |
| Lisinopril | Lisinopril | 57 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | 20 |
| Xarelto | Rivaroxaban | 44 | suppressed |
| Repatha Sureclick | Evolocumab | 39 | suppressed |
| Ranolazine Er | Ranolazine | 38 | 13 |
| Prasugrel Hcl | Prasugrel Hcl | 27 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Potassium Chloride | Potassium Chloride | 18 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 11 |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $36,447.49 · 146 records | Amgen Inc. | ACURATEPrimeAortic Valve XL, AVVIGO Guidance System, CDS - MCT/CEM Monitoring, CLOTTRIEVER BOLD CATHETER, COREVALVE EVOLUT R, CT THROMBECTOMY SYSTEM KIT, Clinical Trial Product, EVOQUE, FARXIGA, FFRANGIO, FLOWTRIEVER, FLOWTRIEVER CATHETER, S, FilterWire EZ, Flextome Cutting Balloon, GEMTESA, General - Atherectomy, General - Balloon Catheters, General - Balloons, General - CT_IC, General - Therapies, General - Ultrasound, MANTA, MITRACLIP, ONYX FRONTIER, REPATHA, SAPIEN 3 Ultra RESILIA, SYMPLICITY G3, Sentinel, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, WAINUA, WATCHMAN, WATCHMAN Access System, WATCHMAN FLX | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error